The gene therapy improved motor functions in children with Duchenne muscular dystrophy two years after treatment ...
Akero Therapeutics announced statistically significant results from a Phase 2b trial of efruxifermin this week, a fibroblast growth factor 21 analog, designed to treat patients with biopsy-confirmed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback